Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Orphazyme A/S (ORPHA.CO)

Copenhagen - Copenhagen Real Time Price. Currency in DKK
Add to watchlist
18.98-0.36 (-1.86%)
At close: 04:59PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close19.34
Open19.50
Bid19.01 x 0
Ask19.30 x 0
Day's Range18.93 - 20.98
52 Week Range18.93 - 109.10
Volume114,237
Avg. Volume129,666
Market Cap663.393M
Beta (5Y Monthly)0.63
PE Ratio (TTM)N/A
EPS (TTM)-22.32
Earnings DateMar 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks

    All You Need to Know About Orphazyme AS Sponsored ADR (ORPH) Rating Upgrade to Buy

    Orphazyme AS Sponsored ADR (ORPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire

    Financial Calendar 2022

    Orphazyme A/SCompany announcement No. 26/2021www.orphazyme.comCompany Registration No. 32266355 Copenhagen – November 19, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces that the company expects to publish financial reports according to the following schedule: Deadline for submission of shareholder proposals to Annual General MeetingFebruary 23, 2022 Annual Report 2021March 15, 2022 Annual General Meeting 2022April 7, 2022 Interim R

  • GlobeNewswire

    Orphazyme establishes a U.S. At-the-Market Offering Program with Cowen

    Orphazyme A/SCompany announcement No. 25/2021Company Registration No. 32266355 Copenhagen – November 4, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces that it has filed with the U.S. Securities and Exchange Commission (the "SEC") a prospectus supplement (“Prospectus”) relating to a U.S. At-the-Market Offering Program, pursuant to which the Company may issue and sell American Depositary Shares ("ADSs") having an aggregate offering p

Advertisement
Advertisement